Active Biotech AB Interim report January - June 2016

LUND, Sweden, Aug. 11, 2016 (GLOBE NEWSWIRE) --

Laquinimod

• The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan
• The study results from both the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) and the Phase 2 study ARPEGGIO, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the first half of 2017
• Positive results concerning laquinimod were presented at the 68th AAN Annual Meeting (American Academy of Neurology), held in Vancouver, Canada, on April 15-21, 2016

Tasquinimod     

• The complete study results of the Phase 3 10TASQ10 study have been published in the Journal of Clinical Oncology
• Out-licensing activities are continuing

ANYARA, Paquinimod (57-57) and SILC (ISI)

• Out-licensing activities are continuing

Financial summary

SEK M	Q2		Q1-Q2		Full Year
	2016	2015	2016	2015	2015
Net sales	3.9	3.2	7.9	6.1	16.3
Operating loss	-14.5	-70.1	-30.6	-127.5	-177.9
Loss for the period	-15.5	-71.4	-32.3	-129.3	-193.5
Loss per share, before and after dilution (SEK)	-0.17	-0.79	-0.36	-1.44	-2.15
Cash and cash equivalents (at the end of the period)			57.4	186.6	103.6

• Refocusing of the company is completed, operating costs reduced by 71% (SEK 95.2 M) compared with 2015  
• The number of employees will be reduced from 56 (June 2015) to 17 by the end of the third quarter of 2016  
• Operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017

For further information, please contact:     

Tomas Leanderson, President and CEO   Tel: [phone]     Hans Kolam, CFO   Tel: [phone]

Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: [phone] Fax: [phone]

The report is also available at www.activebiotech.com.

Active Biotech AB (publ) Interim Report January - June 2016 http://hugin.info/1002/R/2034058/757619.pdf

HUG#2034058